Special Issue "Cutting-Edge Topics in Antipsychotic Drugs"
Deadline for manuscript submissions: 31 January 2021.
Interests: Mechanisms of presynaptic dopaminergic neurotransmission; peripheral dopaminergic signaling in metabolic control
Interests: Metabolic adverse side effects of antipsychotic drugs; central nervous system-based mechanisms of antipsychotic drug action
Antipsychotic drugs (APDs) are commonly prescribed across a range of psychiatric illnesses including schizophrenia, major depression, bipolar disorder, aggressive behaviors, dementia, anxiety, and post-traumatic stress disorder. Consequently, these drugs are some of the most widely prescribed medications in the world. For schizophrenia, at present, APDs remain a cornerstone of treatment. Despite repeated attempts over the decades to find primary or even adjunctive therapies relying on different drug classes, little progress has been made. Consequently, even though currently prescribed APDs are relatively successful in reducing positive symptoms of schizophrenia, they fail to significantly impact critical domains of illness including negative and cognitive symptoms, driving most of the functional impairments associated with schizophrenia. Moreover, these APDs are associated with significant metabolic side effects causing weight gain, increased risk of type 2 diabetes, and profound metabolic disturbances. Furthermore, no class of medication or individual agent is devoid of these metabolic side effects particularly in young, APD-naïve individuals. Surprisingly, despite APDs’ wide prevalence of use and these drugs’ associated therapeutic benefits and liabilities, little is known about their mechanisms of action or the underlying mechanisms responsible for their side effects. This has led more recently to several concerted efforts to both generate new classes of APDs as well as to novels approaches addressing many of the side effects of existing APDs.
The goal of our Special Issue (reviews or original articles) is to present cutting-edge topics concerning APDs. Topics may include:
- APD mechanisms of action (CNS versus peripheral)
- Novel drug-based approaches for different domains of illness
- Controversies in APD action
- Cardio-metabolic side effects and mitigation approaches
- Intrinsic versus iatrogenic metabolic dysfunction in severe mental illness
- Neuroprotective versus deleterious APD actions
- Off-label APD use and/or use in non-psychotic spectrum illness
- Use in prodrome and ultra-high-risk populations
- Motor sequelae of APDs
Prof. Dr. Zachary Z. Freyberg
Dr. Margaret Hahn
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Antipsychotic Drugs
- Dopamine D2 Receptor
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.